1887

Abstract

We have previously shown that in AIDS patients a predominant species of infectious virus can be found which is not neutralized by homologous serum. The presence of the infectious virus was associated with the lack of type-specific antibody directed against the V3 domains of these virions. In contrast to this lack of V3-specific antibody, the other V3 domains of non-infectious virions were well recognized by antibody. To determine whether the lack of a V3-specific antibody response is due to a progressive loss of antibody during human immunodeficiency virus type 1 (HIV-1) infection, we monitored the anti-V3 antibody response in 90 patients over time. Anti-V3 antibodies were monitored by a V3-specific ELISA using 21 different V3 domains as a fusion with glutathione -transferase (GST-V3) based upon sequences from 11 HIV-1 patient isolates and 10 sequences from an HIV-1 B subtype consensus-like GST-V3 expression library. This strictly heterologous screening showed a loss of V3-specific antibodies in 20 out of the 90 patients tested. To study the relevance of these findings we analysed V3 antibody loss in two patients. This strictly autologous antibody screening was performed based upon V3 sequences of the patients’ cell-free virions. In both patients the loss of a V3-specific antibody could be detected in parallel to a decline of CD4 T cells. Moreover, the escape of a distinct V3 variant was shown to correlate closely with the loss of the V3-specific antibody.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-77-10-2403
1996-10-01
2022-05-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/77/10/JV0770102403.html?itemId=/content/journal/jgv/10.1099/0022-1317-77-10-2403&mimeType=html&fmt=ahah

References

  1. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nystrom G., Fenyo E. M. 1990; Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107–112
    [Google Scholar]
  2. Allain J. P., Laurian Y., Paul D. A. 1987; Long-term evaluation of HIV antigen and antibody to p24 and gp41 in patients with haemophilia. New England]ournal of Medicine 317:1114–1121
    [Google Scholar]
  3. Anders R. F. 1986; Multiple cross-reactivities amongst antigens of Plasmodium falciparum impair the development of protective immunity against malaria. Parasite Immunology 8:529–539
    [Google Scholar]
  4. Berman P. W., Groopman J. E., Gregory T., Clapham P., Weiss R. A., Ferriani R., Riddle L., Shimasaki S., Lucas C., Lasky L. A., Eichberg J. W. 1988; HIV-1 challenge of chimpanzees immunized with recombinant gp120. Proceedings of the National Academy of Sciences, USA 85:5200–5204
    [Google Scholar]
  5. Carrow E. W., Vujcic L. K., Glass W. L., Seamon K. B., Rastogi S. C., Hendry R. M., Boulos R., Nzila N., Quinnan G. V. Jr 1991; High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1 MN in sera from Africa and the Americas. AIDS Research and Human Retroviruses 7:831–838
    [Google Scholar]
  6. Cavacini L. A., Ernes C. L., Power J., Underdahl J., Goldstein R., Mayer K., Posner M. R. 1993; Loss of serum antibodies to a conformational epitope of HIV-l/gp120 identified by a human monoclonal antibody is associated with disease progression. Journal of Acquired Immune Deficiency Syndromes 6:1093–1102
    [Google Scholar]
  7. Coombs R. W., Collier A. C., Allain J. P., Nikora B., Leuther M., Gjerset G. F., Corey L. 1989; Plasma viremia in human immunodeficiency virus infection. New England Journal of Medicine 321:1626–1631
    [Google Scholar]
  8. Fenouillet E., Blanes N., Coutellier A., Gluckmann J. C. 1993; Relationship between anti-p24 antibody levels and p24 antigenaemia in HIV-infected patients. AIDS Research and Human Retroviruses 9:1251–1255
    [Google Scholar]
  9. Fenouillet E., Blanes N., Benjouad A., Gliickman J. C. 1995; Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity. Clinical and Experimental Immunology 99:419–424
    [Google Scholar]
  10. Girard M., Kieny M. P., Pinter A., Barre-Sinoussi F., Nara P., Kobe H., Kusumi K., Chaput A., Reinhart T., Muchmore E., Ronco J., Kaczonek M., Garrard E., Gluckman J. C., Fultz P. N. 1991; Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 88:542–546
    [Google Scholar]
  11. Goudsmit J., Debouck C., Meloen R. H., Smit L., Bakker M., Asher D. M., Wolff A. V., Gibbs C. J. Jr, Gajdusek D. C. 1988; Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicts early type-specific antibodies in experimentally infected chimpanzees. Proceedings of the National Academy of Sciences, USA 85:4478–4482
    [Google Scholar]
  12. Goudsmit J., Kuiken C. L., Nara P. L. 1989; Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection. AIDS 3:S119–S123
    [Google Scholar]
  13. Gradoni L., Scalone A., Gramiccia M. 1993; HIV-Leishmania coinfections in Italy: serological data as an indication of the sequence of acquisation of the two infections. Transactions of the Royal Society of Tropical Medicine and Hygiene 87:94–96
    [Google Scholar]
  14. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. 1995; Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–126
    [Google Scholar]
  15. Hogervorst E., Jurriaans S., De Wolf F., Van Wijk A., Wiersma A., Valk M., Roos M., Van Gemen B., Coutinho R., Miedema F., Goudsmit J. 1995; Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. Journal of Infectious Diseases 171:811–821
    [Google Scholar]
  16. Homsy J., Meyer M., Levy J. A. 1990; Serum enhancement of human immunodeficiency virus (HIV) correlates with disease in HIV-infected individuals. Journal of Virology 64:1437–1440
    [Google Scholar]
  17. Jiang S. B., Lin K., Neurath A. R. 1991; Enhancement of human immunodeficiency vims type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41 [Erratum appears in vol.175. p 6211 Journal of Experimental Medicine 174:1557–1563
    [Google Scholar]
  18. Kliks S. G., Shioda T., Haigwood N. L., Levy J. A. 1993; V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency vims type 1. Proceedings of the National Academy of Sciences, USA 90:11518–11522
    [Google Scholar]
  19. Kostrikis L. G., Cao Y., Ngai H., Moore J. P., Ho D. D. 1996; Quantitative analysis of serum neutralization of human immunodeficiency vims type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent semm-dependent infectivity enhancement. Journal of Virology 70:445–458
    [Google Scholar]
  20. Lange J. M. A., Paul D. A., Huisman H. G., De Wolf F., Van Den Berg H., Coutinho R. A., Danner S. A., Van Der Noordaa J., Goudsmit J. 1986; Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. British Medical Journal 293:1459–1462
    [Google Scholar]
  21. LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Langlois A. J., Dreesman G. R., Boswell R. N., Shadduck P., Holley L. H., Karplus M., Bolognesi D. P., Matthews T. J., Emini E. A., Putney S. D. 1990; Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249:932–935
    [Google Scholar]
  22. Layne S. P., Merges M. J., Dembo M., Spouge J. L., Conley S. R., Moore J. P., Raina J. L., Renz H., Gelderblom H. R., Nara P. L. 1992; Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency vims. Virology 189:695–714
    [Google Scholar]
  23. Lu W., Shih W. K., Tourani J.-M., Eme D., Alter H. J., Andrieu J.-M. 1993; Lack of isolate-specific neutralizing activity is correlated with an increased viral burden in rapidly progressing HIV-1-infected patients. AIDS 7:S91–S99
    [Google Scholar]
  24. Macatonia S. E., Lau R., Patterson S., Pinching A. J., Knight S. C. 1990; Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology 71:38–45
    [Google Scholar]
  25. McKeating J. A., Gow J., Goudsmit J., Pearl L. H., Mulder C., Weiss R. A. 1989; Characterization of HIV-1 neutralization escape mutants. AIDS 3:777–784
    [Google Scholar]
  26. Maggi E., Mazzetti M., Ravina A., Annunziato F., De Carli M., Piccini M. P., Manetti R., Carbonari M., Pesce A. M., Del Prete G., Romagnani S. 1994; Ability of HIV to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells. Science 265:244–248
    [Google Scholar]
  27. Montefiori D. C., Graham B. S., Kliks S., Wright P. F. 1992; Serum antibodies to HIV-1 in recombinant vaccinia vims recipients boosted with purified recombinant gp160. Journal of Clinical Immunology 12:429–439
    [Google Scholar]
  28. Moore J. P., Cao Y., Ho D. D., Koup R. A. 1994; Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. Journal of Virology 68:5142–5155
    [Google Scholar]
  29. Moore J. P., Cao Y., Leu J., Qin L., Korber B., Ho D. D. 1996; Inter- and intraclade neutralization of human immunodeficiency vims type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gpl20 antigenic serotypes. Journal of Virology 70:427–444
    [Google Scholar]
  30. Najera I., Holguin A., Quinones Mateu M. E., Munoz Fernandez M. A., Najera R., Lopez Galindez C., Domingo E. 1995; Pol gene quasispecies of human immunodeficiency virus: mutations associated with dmg resistance in vims from patients undergoing no dmg therapy. Journal of Virology 69:23–31
    [Google Scholar]
  31. Nara P. L., Smit L., Dunlop N., Hatch W., Merges M., Waters D., Kelliher J., Gallo R. C., Fischinger P. J., Goudsmit J. 1990; Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency vims type 1 IIIB infection of chimpanzees. Journal of Virology 64:3779–3791
    [Google Scholar]
  32. Page M., Vella C., Corcoran T., Dilger P., Ling C., Heath A., Thorpe R. 1992; Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS. AIDS 6:441–446
    [Google Scholar]
  33. Piatak M., Saag M. S. Jr, Yang L. C., Kappes J. C., Luk K. C., Hahn B. H., Shaw G. M., Lifson J. D. 1993; High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749–1754
    [Google Scholar]
  34. Pincus S. H., Messer K. G., Nara P. L., Blattner W. A., Colclough G., Reitz M. 1994; Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. Journal of Clinical Investigation 93:2505–2513
    [Google Scholar]
  35. Pircher H., Moskophidis D., Rohrer U., Burki K., Hengartner H., Zinkernagel R. M. 1990; Viral escape by selection of cytotoxic T cell-resistant vims variants in vivo . Nature 346:629–633
    [Google Scholar]
  36. Pulendran B., Smith K. G. C., Nossal G. J. V. 1995; Soluble antigen can impede affinity maturation and the germinal center reaction but enhance extrafollicular immunoglobulin production. Journal of Immunology 155:1141–1150
    [Google Scholar]
  37. Rinaldo C., Huang X. L., Fan Z., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cottrill M., Gupta P. 1995; High levels of anti-human immunodeficiency vims type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-l-infected long-term non-progressors. Journal of Virology 69:5838–5842
    [Google Scholar]
  38. Rosenberg Z. F., Fauci A. S. 1988; Immunopathogenic mechanisms in human immunodeficiency vims (HIV) infections. Annals of the New York Academy of Sciences 546:164–174
    [Google Scholar]
  39. Schnittman S. M., Lane H. C., Greenhouse J. J., Justement J. S., Baseler M., Fauci A. S. 1990; Preferential infection of CD4+ memory cells by human immunodeficiency vims type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proceedings of the National Academy of Sciences, USA 87:6058–6062
    [Google Scholar]
  40. Schreiber M., Petersen H., Wachsmuth C., Müller H., Hufert F. T., Schmitz H. 1994; Antibodies of symptomatic human immunodeficiency vims type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum. Journal of Virology 68:3908–3916
    [Google Scholar]
  41. Spear G. T., Takefman D. M., Sharpe S., Ghassemi M., ZollaPazner S. 1994; Antibodies to the HIV-1 V3 loop in semm from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 204:609–615
    [Google Scholar]
  42. Strunnikova N., Ray S. C., Livingston R. A., Rubalcaba E., Viscidi R. P. 1995; Convergent evolution within the V3 loop domain of human immunodeficiency vims type 1 in association with disease progression. Journal of Virology 69:7548–7558
    [Google Scholar]
  43. von Gegerfelt A., Albert J., Morfeldt-Manson L., Broliden K., Fenyo E. M. 1991; Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology 185:162–168
    [Google Scholar]
  44. Wabwire Mangen F., Shift C. L., Valhov D., Kline R., Serwadda D., Sewankambo N. K., Mugerwa R. D., Quinn T. C. 1989; Immunological effects of HIV-1 infection on the humoral response to malaria in an Africa population. American Journal of Tropical Medicine and Hygiene 41:5504–5511
    [Google Scholar]
  45. Wain Hobson S. 1995; Virological mayhem. Nature 373:102
    [Google Scholar]
  46. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H., Saag M. S., Shaw G. M. 1995; Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117–122
    [Google Scholar]
  47. Zwart G., Langedijk H., Van Der Hoek L., De Jong J. J., Wolfs T. F. W., Ramautarsing C., Bakker M., De Ronde A., Goudsmit J. 1991; Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 181:481–489
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-77-10-2403
Loading
/content/journal/jgv/10.1099/0022-1317-77-10-2403
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error